https://app.readthrough.bio/stories/exelixis-registers-phase-2-trial-pairing-zanzalintinib-with-027f3e2026-09-30monthly0.5 https://app.readthrough.bio/stories/neurocrine-registers-phase-2-trial-of-nbip-01435-in-classic-congenital-0c91022026-10-01monthly0.5 https://app.readthrough.bio/stories/abbvie-registers-phase-1-trial-comparing-upadacitinib-tofacitinib-126c452026-09-29monthly0.5 https://app.readthrough.bio/stories/viking-therapeutics-registers-phase-1-trial-of-obesity-candidate-vk3019-29f6252026-09-30monthly0.5 https://app.readthrough.bio/stories/biontech-phase-3-trial-of-variant-adapted-bnt162b2-covid-vaccine-31fa0f2026-09-29monthly0.5 https://app.readthrough.bio/stories/roche-posts-imvigor011-bladder-cancer-results-registers-three-456b5d2026-09-29monthly0.5 https://app.readthrough.bio/stories/takeda-posts-results-for-tak-881-vs-hyqvia-pharmacokinetic-study-in-470af32026-10-01monthly0.5 https://app.readthrough.bio/stories/gsk-registers-gist-legacy-study-for-velzatinib-toddler-pneumococcal-6346b42026-09-29monthly0.5 https://app.readthrough.bio/stories/novartis-logs-four-registry-updates-gmg-phase-3-active-lupus-car-t-6d4e952026-09-29monthly0.5 https://app.readthrough.bio/stories/crispr-therapeutics-registers-phase-1-2-trial-of-ctx460-for-aatd-8f0f542026-10-01monthly0.5 https://app.readthrough.bio/stories/corcept-s-miricorilant-masld-phase-1-study-completed-university-of-a0d4972026-10-01monthly0.5 https://app.readthrough.bio/stories/peking-university-registers-finerenone-semaglutide-trial-for-obesity-a2faa52026-10-01monthly0.5 https://app.readthrough.bio/stories/boehringer-ingelheim-registers-phase-1-bioequivalence-trial-for-b705462026-09-30monthly0.5 https://app.readthrough.bio/stories/regeneron-s-phase-1-2-glaucoma-trial-for-regn22530-recruiting-at-single-b70b862026-09-29monthly0.5 https://app.readthrough.bio/stories/sanofi-s-sar444881-tumor-trial-results-posted-after-early-stop-bb76252026-09-30monthly0.5 https://app.readthrough.bio/stories/janssen-posts-phase-3-results-for-expec9v-vaccine-trial-in-older-adults-c7d8922026-09-29monthly0.5 https://app.readthrough.bio/stories/merck-s-keyvibe-005-basket-study-completes-with-results-posted-after-cd1ee72026-09-29monthly0.5 https://app.readthrough.bio/stories/amgen-s-phase-3-maritide-osa-trial-status-update-active-not-recruiting-d916e32026-09-30monthly0.5 https://app.readthrough.bio/stories/novo-nordisk-registers-two-phase-3-amaze-trials-for-oral-and-injectable-e4652b2026-09-29monthly0.5 https://app.readthrough.bio/stories/bms-registers-observational-remap-hcm-study-of-mavacamten-in-chinese-f1a9542026-09-30monthly0.5 https://app.readthrough.bio/stories/bayer-registers-observational-mexico-study-of-finerenone-in-t2d-and-ckd-05458d2026-09-27monthly0.5 https://app.readthrough.bio/stories/acadia-s-acp-204-open-label-extension-study-in-lewy-body-dementia-0bab4f2026-09-30monthly0.5 https://app.readthrough.bio/stories/astrazeneca-linked-studies-chio3-results-posted-two-new-early-stage-1188922026-09-28monthly0.5 https://app.readthrough.bio/stories/ollin-biosciences-registers-two-phase-3-trials-of-oln324-for-diabetic-137b8f2026-09-28monthly0.5 https://app.readthrough.bio/stories/tiziana-doses-first-als-patients-with-intranasal-foralumab-in-banyan-172c1a2026-09-28monthly0.5 https://app.readthrough.bio/stories/novartis-updates-scemblix-label-registers-pv-real-world-study-and-cad-192b252026-09-25monthly0.5 https://app.readthrough.bio/stories/abbvie-registers-first-in-human-phase-1-trial-for-oral-abbv-1162-193ae62026-09-25monthly0.5 https://app.readthrough.bio/stories/roche-s-two-phase-iii-trontinemab-alzheimer-s-trials-now-listed-as-26e8e32026-09-25monthly0.5 https://app.readthrough.bio/stories/trial-registered-testing-jornay-pm-for-adhd-with-cannabis-use-disorder-2b72d72026-09-28monthly0.5 https://app.readthrough.bio/stories/alveus-registers-phase-2-trial-of-alv-100-for-weight-loss-maintenance-2e52c32026-09-28monthly0.5 https://app.readthrough.bio/stories/madrigal-registers-phase-4-safety-study-of-rezdiffra-with-diabetes-2fd2322026-09-30monthly0.5 https://app.readthrough.bio/stories/okyo-registers-phase-3-trial-of-urcosimod-for-neuropathic-corneal-pain-306fbe2026-09-28monthly0.5 https://app.readthrough.bio/stories/bms-appears-across-three-trials-spanning-screening-safety-and-325e832026-09-27monthly0.5 https://app.readthrough.bio/stories/novo-nordisk-registers-phase-3-trial-for-denecimig-in-acquired-3501002026-09-25monthly0.5 https://app.readthrough.bio/stories/merck-kgaa-registers-elowen-lte-phase-3-lupus-study-and-mirdametinib-3db0ae2026-09-28monthly0.5 https://app.readthrough.bio/stories/palisade-bio-registers-phase-2-trial-of-pali-2108-in-ulcerative-colitis-42f9f42026-09-30monthly0.5 https://app.readthrough.bio/stories/moleculin-closes-part-a-enrollment-in-miracle-aml-trial-at-89-one-4c4ff12026-09-30monthly0.5 https://app.readthrough.bio/stories/gsk-linked-trials-alector-s-phase-3-ftd-study-terminated-phase-2-brca-6111202026-09-27monthly0.5 https://app.readthrough.bio/stories/tvardi-s-tti-101-breast-cancer-trial-posts-results-after-early-657b582026-09-28monthly0.5 https://app.readthrough.bio/stories/innovent-registers-phase-ii-gout-trial-for-ibi3011-phase-i-hypertension-673b822026-09-28monthly0.5 https://app.readthrough.bio/stories/eledon-registers-phase-3-trial-comparing-tegoprubart-with-tacrolimus-in-6ccdf52026-09-27monthly0.5 https://app.readthrough.bio/stories/insmed-s-phase-1-trial-of-ins1033-in-healthy-volunteers-is-recruiting-6f8aed2026-09-26monthly0.5 https://app.readthrough.bio/stories/university-of-alberta-registers-phase-4-lemborexant-nocturia-trial-with-8019852026-09-28monthly0.5 https://app.readthrough.bio/stories/terns-merck-complete-two-phase-1-tern-701-trials-in-healthy-adults-824cde2026-09-27monthly0.5 https://app.readthrough.bio/stories/kaiser-permanente-registers-covid-vaccine-choice-messaging-trial-with-9596c62026-09-25monthly0.5 https://app.readthrough.bio/stories/corcept-s-rosella-phase-3-posts-results-for-relacorilant-plus-nab-9b6dca2026-09-27monthly0.5 https://app.readthrough.bio/stories/loxo-posts-phase-3-pirtobrutinib-results-five-more-lilly-linked-trials-a3053c2026-09-26monthly0.5 https://app.readthrough.bio/stories/takeda-terminates-gdx012-aml-trial-by-sponsor-decision-results-posted-b02d852026-09-28monthly0.5 https://app.readthrough.bio/stories/gilead-registers-two-phase-2-trials-pbc-combo-study-and-weekly-oral-hiv-b48c3a2026-09-27monthly0.5 https://app.readthrough.bio/stories/astrazeneca-completes-phase-1-laroprovstat-ezetimibe-bioavailability-b9b0352026-09-29monthly0.5 https://app.readthrough.bio/stories/lilly-posts-lyumjev-safety-results-in-india-registers-new-alzheimer-s-c3f0152026-09-29monthly0.5 https://app.readthrough.bio/stories/pfizer-registers-two-phase-3-trials-tilrekimig-copd-extension-rsvpref-c4986d2026-09-25monthly0.5 https://app.readthrough.bio/stories/vanderbilt-registers-phase-2-toripalimab-trial-in-esophageal-cancer-cf0ebc2026-09-28monthly0.5 https://app.readthrough.bio/stories/hutchmed-begins-global-phase-ia-trial-of-hmpl-a830-in-solid-tumors-cffbc92026-09-29monthly0.5 https://app.readthrough.bio/stories/novlead-registers-post-market-study-of-inowill-n200-nitric-oxide-device-d3056d2026-09-28monthly0.5 https://app.readthrough.bio/stories/ionis-registers-phase-3-trial-of-obudanersen-for-angelman-syndrome-due-d5779b2026-09-29monthly0.5 https://app.readthrough.bio/stories/viking-therapeutics-registers-phase-1-study-of-vk2735-in-obese-adults-ec73f02026-09-28monthly0.5 https://app.readthrough.bio/stories/boehringer-ingelheim-registers-phase-ib-ii-trial-pairing-obrixtamig-f48db32026-09-29monthly0.5 https://app.readthrough.bio/stories/xenon-posts-phase-2-results-for-xen1101-in-major-depressive-disorder-1cbba82026-09-28monthly0.5 https://app.readthrough.bio/stories/j-j-vision-study-posts-results-hip-depression-contact-lens-trials-2191c22026-09-27monthly0.5 https://app.readthrough.bio/stories/neurocrine-registers-phase-2a-trial-of-nbi-1117567-in-mild-to-moderate-2a7b4e2026-09-28monthly0.5 https://app.readthrough.bio/stories/fda-approves-manufacturing-supplement-for-gland-s-epinephrine-anda-36a3b12026-09-28monthly0.5 https://app.readthrough.bio/stories/corvus-registers-phase-1b-trial-of-soquelitinib-in-hidradenitis-4d2f612026-09-28monthly0.5 https://app.readthrough.bio/stories/regeneron-registers-two-new-trials-prion-disease-gene-therapy-and-hs-5918d12026-09-25monthly0.5 https://app.readthrough.bio/stories/united-therapeutics-tyvaso-dpi-nda214324-suppl-7-approved-6e4ba82026-09-30monthly0.5 https://app.readthrough.bio/stories/odense-university-hospital-registers-opticare-cardiorenal-clinic-trial-9765692026-09-28monthly0.5 https://app.readthrough.bio/stories/amgen-registers-new-phase-1-trial-comparing-two-maritide-drug-product-a25f1f2026-09-25monthly0.5 https://app.readthrough.bio/stories/attovia-registers-phase-2-trial-of-atto-1310-for-chronic-pruritus-of-ac502f2026-09-28monthly0.5 https://app.readthrough.bio/stories/lilly-s-orforglipron-posts-phase-3-diabetes-results-four-new-trials-afe1952026-09-25monthly0.5 https://app.readthrough.bio/stories/university-of-zurich-registers-phase-2-safusidenib-trial-in-idh1-mutant-b051912026-09-27monthly0.5 https://app.readthrough.bio/stories/sinovac-registers-two-new-not-yet-recruiting-trials-for-pcv13-and-anflu-b59af82026-09-27monthly0.5 https://app.readthrough.bio/stories/harrow-registers-phase-3-trial-of-triesence-for-pain-and-inflammation-ba56d32026-09-28monthly0.5 https://app.readthrough.bio/stories/janssen-registers-phase-2-trial-of-riptac-drug-jnj-101556143-in-bd7d712026-09-28monthly0.5 https://app.readthrough.bio/stories/roche-posts-hcc-trial-results-registers-five-new-studies-across-cancer-c232dd2026-09-25monthly0.5 https://app.readthrough.bio/stories/upstream-bio-posts-vibrant-phase-2-results-for-verekitug-in-nasal-polyps-c9ba842026-09-28monthly0.5 https://app.readthrough.bio/stories/regeneron-s-eylea-hd-posts-phase-3b-safety-results-dupilumab-keloid-cbd8442026-09-25monthly0.5 https://app.readthrough.bio/stories/gsk-s-ipf-drug-gsk3915393-fails-phase-2-on-futility-expanded-access-dae1fe2026-09-27monthly0.5 https://app.readthrough.bio/stories/cardiovision-registers-two-stepped-wedge-trials-for-torch-transplant-e1c7172026-09-28monthly0.5 https://app.readthrough.bio/stories/madrigal-registers-new-phase-1b-trial-testing-resmetirom-in-mash-f0309e2026-09-27monthly0.5 https://app.readthrough.bio/stories/arrowhead-s-aro-muc5ac-trial-marked-terminated-for-business-reasons-0b38d22026-09-27monthly0.5 https://app.readthrough.bio/stories/recursion-registers-phase-1-2-trial-of-rec-7735-in-pik3ca-h1047r-solid-117c3e2026-09-28monthly0.5 https://app.readthrough.bio/stories/trial-tests-tislelizumab-plus-anlotinib-as-consolidation-therapy-in-13b1ab2026-09-27monthly0.5 https://app.readthrough.bio/stories/novartis-registers-phase-3-urticaria-pruritus-trials-posts-malaria-and-1f34352026-09-25monthly0.5 https://app.readthrough.bio/stories/uva-registers-phase-1b-2-trial-of-verastem-s-avutometinib-defactinib-in-21a9782026-09-27monthly0.5 https://app.readthrough.bio/stories/amneal-s-itraconazole-anda-gets-labeling-supplement-approved-by-fda-278ed42026-09-27monthly0.5 https://app.readthrough.bio/stories/novo-nordisk-registers-two-phase-1-pk-trials-for-zenagamtide-and-2818242026-09-25monthly0.5 https://app.readthrough.bio/stories/aconcagua-bio-s-accg-2671-obesity-trial-recruiting-under-structure-35ce892026-09-28monthly0.5 https://app.readthrough.bio/stories/pfizer-registers-four-trials-rsv-vaccine-atopic-dermatitis-sleep-apnea-3a5da12026-09-25monthly0.5 https://app.readthrough.bio/stories/novartis-updates-zortress-label-advances-fanconi-anemia-and-igan-trials-3d2fff2026-09-25monthly0.5 https://app.readthrough.bio/stories/lilly-registers-three-new-early-trials-olomorasib-in-colorectal-cancer-4921972026-09-25monthly0.5 https://app.readthrough.bio/stories/novo-nordisk-registers-phase-3-obesity-trial-in-japan-new-cagrisema-4fb0b22026-09-27monthly0.5 https://app.readthrough.bio/stories/fda-approves-labeling-supplement-for-mylan-s-amnesteem-isotretinoin-519db02026-09-28monthly0.5 https://app.readthrough.bio/stories/jazz-linked-lurbinectedin-gi-trial-posts-results-new-jzp269-phase-1-5cab212026-09-27monthly0.5 https://app.readthrough.bio/stories/biontech-posts-results-for-mpox-vaccine-bnt166a-phase-i-ii-trial-60f9302026-09-27monthly0.5 https://app.readthrough.bio/stories/sun-pharmaceutical-industries-dextroamp-saccharate-amp-aspartate-6517132026-09-28monthly0.5 https://app.readthrough.bio/stories/amgen-updates-imdelltra-label-via-bla-supplement-registers-romosozumab-6c45372026-09-25monthly0.5 https://app.readthrough.bio/stories/zydus-pharms-gets-fda-approvals-for-lacosamide-labeling-update-and-6df6ca2026-09-28monthly0.5 https://app.readthrough.bio/stories/insmed-posts-phase-2a-results-for-opscf-in-moderate-to-severe-atopic-6ee0242026-09-28monthly0.5 https://app.readthrough.bio/stories/lipocine-registers-phase-3-study-of-oral-lpcn-1154a-for-postpartum-6feffd2026-09-28monthly0.5 https://app.readthrough.bio/stories/kymera-registers-phase-1-crossover-trial-testing-oral-formulations-of-751a1f2026-09-28monthly0.5 https://app.readthrough.bio/stories/macrogenics-registers-phase-1-first-in-human-trial-of-adc-mgc030-in-81298c2026-09-28monthly0.5 https://app.readthrough.bio/stories/imprimisrx-nj-recalls-ophthalmic-solution-for-subpotency-class-iii-9097672026-09-28monthly0.5 https://app.readthrough.bio/stories/cardiovision-registers-heart-failure-pathway-trial-unrelated-acp-and-94e6af2026-09-27monthly0.5 https://app.readthrough.bio/stories/fda-clears-three-labeling-supplements-for-palonosetron-letrozole-a1759b2026-09-28monthly0.5 https://app.readthrough.bio/stories/attovia-registers-phase-1-trial-of-atto-1091-for-ulcerative-colitis-a5678a2026-09-27monthly0.5 https://app.readthrough.bio/stories/pfizer-linked-studies-registered-rimegepant-chemo-trial-hiba-a7bde92026-09-25monthly0.5 https://app.readthrough.bio/stories/incyte-posts-terminated-phase-1-krasg12c-combo-results-registers-new-adf2692026-09-27monthly0.5 https://app.readthrough.bio/stories/abbvie-registers-phase-3-trial-of-telisotuzumab-adizutecan-in-nsclc-c3b4f52026-09-25monthly0.5 https://app.readthrough.bio/stories/argenx-registers-phase-2-trial-of-empasiprubart-for-guillain-barr-d5339e2026-09-28monthly0.5 https://app.readthrough.bio/stories/copd-foundation-registers-delivery-trial-with-viatris-pari-theravance-dafe142026-09-28monthly0.5 https://app.readthrough.bio/stories/mirum-registers-phase-2-trial-of-maralixibat-for-cholestasis-of-e5fe0b2026-09-28monthly0.5 https://app.readthrough.bio/stories/incyte-registers-phase-2-trial-of-inca33890-in-mrd-positive-colorectal-ee50f32026-09-27monthly0.5 https://app.readthrough.bio/stories/astrazeneca-registers-phase-3-ovarian-cancer-adc-trial-and-phase-1-hmpv-f0f0c02026-09-25monthly0.5 https://app.readthrough.bio/stories/summit-therapeutics-registers-phase-2-3-harmoni-gu1-trial-in-urothelial-f32c242026-09-28monthly0.5 https://app.readthrough.bio/stories/abbvie-sponsors-new-abbv-253-solid-tumor-trial-collaborates-on-00a1a42026-09-25monthly0.5 https://app.readthrough.bio/stories/bicara-therapeutics-updates-registry-record-nct07807163-recruiting-0ff2652026-09-28monthly0.5 https://app.readthrough.bio/stories/annexon-registers-phase-3-extension-study-of-vonaprument-for-geographic-132d8d2026-09-28monthly0.5 https://app.readthrough.bio/stories/bioage-labs-registers-phase-2-study-of-oral-bge-102-in-diabetic-macular-14041f2026-09-27monthly0.5 https://app.readthrough.bio/stories/abivax-posts-phase-3-results-for-obefazimod-in-ulcerative-colitis-1bf0da2026-09-28monthly0.5 https://app.readthrough.bio/stories/arcutis-posts-results-for-roflumilast-psoriasis-extension-trial-1ef9f42026-09-28monthly0.5 https://app.readthrough.bio/stories/king-s-college-hospital-registers-pk-study-of-gilead-partnered-taf-2d9c0b2026-09-27monthly0.5 https://app.readthrough.bio/stories/apnimed-posts-phase-3-synairgy-results-for-ad109-in-obstructive-sleep-3f3b732026-09-28monthly0.5 https://app.readthrough.bio/stories/sun-pharma-gets-labeling-supplement-approved-for-carbidopa-and-levodopa-4191b02026-09-28monthly0.5 https://app.readthrough.bio/stories/aardvark-posts-phase-2-results-for-ard-101-in-prader-willi-syndrome-481cc52026-09-28monthly0.5 https://app.readthrough.bio/stories/teva-gets-labeling-supplement-approved-for-injectable-paclitaxel-6e07d22026-09-28monthly0.5 https://app.readthrough.bio/stories/wave-posts-results-for-terminated-wve-004-ole-study-in-c9orf72-als-ftd-75a1902026-09-28monthly0.5 https://app.readthrough.bio/stories/sanofi-registers-phase-2b-hidradenitis-suppurativa-trial-rsv-hmpv-7ce9b22026-09-25monthly0.5 https://app.readthrough.bio/stories/janux-therapeutics-opens-phase-1-combo-trial-of-janx013-and-janx007-in-8a3fd02026-09-28monthly0.5 https://app.readthrough.bio/stories/roche-posts-results-for-lebrikizumab-copd-trial-crovalimab-pediatric-a13d482026-09-25monthly0.5 https://app.readthrough.bio/stories/astrazeneca-posts-capitello-281-results-in-pten-deficient-prostate-b4b5ae2026-09-25monthly0.5 https://app.readthrough.bio/stories/sutro-biopharma-registers-phase-1-first-in-human-trial-of-adc-stro-006-baf2382026-09-28monthly0.5 https://app.readthrough.bio/stories/regeneron-registers-two-new-cemiplimab-trials-in-skin-cancer-and-early-c6f0232026-09-27monthly0.5 https://app.readthrough.bio/stories/mayo-clinic-registers-phase-3-trial-of-deka-twiist-insulin-pump-in-c82a532026-09-27monthly0.5 https://app.readthrough.bio/stories/strides-pharma-gets-manufacturing-supplement-approved-for-polyethylene-ce4f502026-09-28monthly0.5 https://app.readthrough.bio/stories/revolution-medicines-registers-phase-3-rasolute-309-in-kras-g12d-e1fc2a2026-09-27monthly0.5 https://app.readthrough.bio/stories/viatris-registers-phase-4-abuse-potential-trial-of-gabapentin-plus-e53c1b2026-09-28monthly0.5 https://app.readthrough.bio/stories/moonlake-posts-phase-2-results-for-sonelokimab-in-psoriatic-arthritis-ef4d662026-09-28monthly0.5 https://app.readthrough.bio/stories/johns-hopkins-registers-phase-2-heroic-caregiver-trial-in-advanced-016b112026-09-28monthly0.5 https://app.readthrough.bio/stories/insmed-registers-phase-3-trial-of-inhaled-tpip-for-progressive-0f93832026-09-25monthly0.5 https://app.readthrough.bio/stories/fda-approves-labeling-supplement-for-children-s-xyzal-allergy-24hr-oral-10f4c12026-09-25monthly0.5 https://app.readthrough.bio/stories/javelin-bladder-medley-posts-results-avelumab-combos-tested-as-172da52026-09-27monthly0.5 https://app.readthrough.bio/stories/novartis-roundup-itp-real-world-data-completed-three-trials-registered-176bec2026-09-25monthly0.5 https://app.readthrough.bio/stories/ucsd-registers-phase-2-study-of-low-dose-dexamethasone-to-prevent-248c0a2026-09-28monthly0.5 https://app.readthrough.bio/stories/beigene-posts-results-for-zanidatamab-combo-trial-in-her2-positive-2d66b92026-09-27monthly0.5 https://app.readthrough.bio/stories/incyte-registers-phase-3-maestra-3-trial-in-cyclin-e1-overexpressing-3e35b12026-09-27monthly0.5 https://app.readthrough.bio/stories/abbvie-posts-imgn632-bpdcn-results-opens-noa-lift-filler-trial-vs-volift-4799db2026-09-25monthly0.5 https://app.readthrough.bio/stories/ideaya-registers-phase-3-adjuvant-trial-of-darovasertib-plus-crizotinib-49697e2026-09-27monthly0.5 https://app.readthrough.bio/stories/arcturus-posts-phase-1-2-results-for-arct-2304-self-amplifying-mrna-flu-4b580c2026-09-28monthly0.5 https://app.readthrough.bio/stories/sun-pharma-gets-fda-labeling-supplement-approval-for-oxcarbazepine-oral-5a39eb2026-09-28monthly0.5 https://app.readthrough.bio/stories/cervomed-eip-pharma-trial-posts-results-for-neflamapimod-in-lewy-body-5b45572026-09-28monthly0.5 https://app.readthrough.bio/stories/edgewise-therapeutics-registers-phase-2-equinox-hfpef-study-of-edg-15400-66aea92026-09-25monthly0.5 https://app.readthrough.bio/stories/samsung-bioepis-gets-label-supplement-approved-for-byooviz-ranibizumab-6e52982026-09-27monthly0.5 https://app.readthrough.bio/stories/bms-logs-three-fda-label-approvals-and-posts-results-for-melanoma-combo-70603d2026-09-28monthly0.5 https://app.readthrough.bio/stories/novo-nordisk-registers-phase-3-zenagamtide-trial-in-t2d-and-first-in-730a602026-09-27monthly0.5 https://app.readthrough.bio/stories/fate-therapeutics-registers-phase-1-2-trial-of-ft839-across-five-8761312026-09-28monthly0.5 https://app.readthrough.bio/stories/nervgen-registers-phase-3-restore-trial-of-nvg-291-in-chronic-spinal-a5e79b2026-09-28monthly0.5 https://app.readthrough.bio/stories/cadila-pharms-wins-anda-labeling-supplement-approval-for-acyclovir-aa896d2026-09-28monthly0.5 https://app.readthrough.bio/stories/astrazeneca-week-imfinzi-label-update-assure-cll-results-posted-four-b2862d2026-09-27monthly0.5 https://app.readthrough.bio/stories/roswell-park-s-phase-ii-cpx-351-trial-in-younger-secondary-aml-patients-c5eda52026-09-27monthly0.5 https://app.readthrough.bio/stories/gsk-registers-phase-3-trials-for-mrna-flu-vaccine-and-prostate-cancer-d0bca52026-09-27monthly0.5 https://app.readthrough.bio/stories/amgen-registers-phase-4-trial-testing-repatha-s-effect-on-coronary-dd5f572026-09-25monthly0.5 https://app.readthrough.bio/stories/lilly-posts-phase-3-orforglipron-results-two-more-programs-report-e158212026-09-25monthly0.5 https://app.readthrough.bio/stories/actavis-labs-fl-secures-four-labeling-supplement-approvals-for-e15ac42026-09-28monthly0.5 https://app.readthrough.bio/stories/pfizer-s-rimegepant-phase-3-in-china-posts-results-four-more-trials-e3d8632026-09-25monthly0.5 https://app.readthrough.bio/stories/zai-lab-registers-phase-3-trial-for-zl-1310-in-lung-cancer-and-real-e77e812026-09-28monthly0.5 https://app.readthrough.bio/stories/inovio-s-uca-001-trial-completes-results-posted-for-ino-5401-combo-in-ef55f12026-09-27monthly0.5 https://app.readthrough.bio/stories/sanofi-s-itepekimab-copd-mechanism-study-aerify-3-posts-results-after-f57dec2026-09-25monthly0.5 https://app.readthrough.bio/stories/sanofi-registers-phase-3-extension-study-for-lunsekimig-in-copd-named-1d09372026-09-27monthly0.5 https://app.readthrough.bio/stories/bms-posts-results-for-two-opdualag-opdivo-trials-registry-shows-cobenfy-224c642026-09-25monthly0.5 https://app.readthrough.bio/stories/boehringer-ingelheim-registers-phase-3-veranda-iim-trial-of-3181582026-10-01monthly0.5 https://app.readthrough.bio/stories/altimmune-registers-phase-3-pemvidutide-trial-in-mash-under-performa-33e7882026-09-28monthly0.5 https://app.readthrough.bio/stories/sinovac-recruits-phase-iii-hepatitis-a-study-registers-ev71-bridging-3637342026-09-27monthly0.5 https://app.readthrough.bio/stories/amgen-posts-results-for-rocatinlimab-ad-trial-daxdilimab-myositis-study-41be712026-09-25monthly0.5 https://app.readthrough.bio/stories/biontech-posts-results-for-phase-i-iia-malaria-rna-vaccine-trial-chmi-496d982026-09-27monthly0.5 https://app.readthrough.bio/stories/uke-registers-balance-trial-comparing-balloon-and-self-expanding-tavi-5a1ad52026-09-28monthly0.5 https://app.readthrough.bio/stories/lilly-registers-two-new-trials-orforglipron-in-china-mirikizumab-6b90072026-09-25monthly0.5 https://app.readthrough.bio/stories/abbvie-registers-phase-3-trial-of-etentamig-vs-dara-cybord-in-al-77ea442026-09-25monthly0.5 https://app.readthrough.bio/stories/cardior-posts-phase-2-hf-revert-results-for-cdr132l-in-post-mi-heart-80e0c92026-09-25monthly0.5 https://app.readthrough.bio/stories/niaid-led-impaact-2026-pharmacokinetic-study-terminated-early-results-8f07582026-09-27monthly0.5 https://app.readthrough.bio/stories/unc-registers-phase-4-trial-testing-phathom-s-vonoprazan-in-barrett-s-9c8ec82026-09-28monthly0.5 https://app.readthrough.bio/stories/j-j-linked-filings-phase-2-teclistamab-trial-in-waldenstrom-s-two-eye-9cbda42026-09-27monthly0.5 https://app.readthrough.bio/stories/takeda-s-gattex-gets-rems-related-supplement-approved-by-fda-9f89372026-09-27monthly0.5 https://app.readthrough.bio/stories/astrazeneca-posts-mitchell-asthma-results-registers-selene-1-obesity-aafd7f2026-09-25monthly0.5 https://app.readthrough.bio/stories/two-new-registry-studies-posted-obesity-linked-heart-failure-and-long-b0d9692026-09-28monthly0.5 https://app.readthrough.bio/stories/immunitybio-registers-phase-2a-trial-of-nai-in-sepsis-with-persistent-b148992026-09-27monthly0.5 https://app.readthrough.bio/stories/vertex-collaborator-registers-exploratory-trial-of-journavx-for-ankle-b61be22026-10-01monthly0.5 https://app.readthrough.bio/stories/vertex-registers-phase-1-drug-interaction-study-for-vx-407-with-oral-be81052026-10-01monthly0.5 https://app.readthrough.bio/stories/pfizer-posts-met097-obesity-results-registers-new-phase-3-obesity-and-d39e292026-09-25monthly0.5 https://app.readthrough.bio/stories/novartis-linked-melanoma-trial-posts-results-new-itp-preference-survey-d97f7f2026-09-25monthly0.5 https://app.readthrough.bio/stories/gsk-posts-results-for-2021-covid-19-sam-vaccine-trial-advances-four-e6f05a2026-09-27monthly0.5 https://app.readthrough.bio/stories/jazz-posts-results-for-xywav-sleep-study-registers-new-zanidatamab-real-e76ff62026-09-27monthly0.5 https://app.readthrough.bio/stories/johns-hopkins-registers-phase-2-trial-of-revolution-medicines-f9370d2026-09-27monthly0.5 https://app.readthrough.bio/stories/revolution-medicines-registers-phase-3-zoldonrasib-trial-for-ras-g12d-0ade8d2026-09-27monthly0.5 https://app.readthrough.bio/stories/novartis-updates-leqvio-label-ms-study-recruiting-thyroid-study-not-yet-0f2f932026-09-25monthly0.5 https://app.readthrough.bio/stories/novo-nordisk-registers-real-world-cardiometabolic-study-using-turkish-1381502026-09-25monthly0.5 https://app.readthrough.bio/stories/amgen-registers-phase-3-trial-comparing-subcutaneous-and-iv-tarlatamab-16e3fb2026-09-27monthly0.5 https://app.readthrough.bio/stories/incyte-backed-trials-osu-tests-pemigatinib-cycling-regimen-ohsu-starts-1d0c722026-09-27monthly0.5 https://app.readthrough.bio/stories/viatris-ocuphire-trial-results-posted-amnesteem-label-update-gabapentin-2b2d012026-09-28monthly0.5 https://app.readthrough.bio/stories/enanta-posts-results-for-phase-2b-edp-938-rsv-trial-in-high-risk-adults-2b9fac2026-09-28monthly0.5 https://app.readthrough.bio/stories/biofrontera-s-phase-3-ameluz-trial-for-ak-on-extremities-neck-posts-2f95072026-09-28monthly0.5 https://app.readthrough.bio/stories/annexon-posts-results-for-completed-phase-2a-anx005-study-in-huntington-329e2e2026-09-28monthly0.5 https://app.readthrough.bio/stories/novo-nordisk-posts-pioneer-teens-results-registers-three-new-trials-for-3dba012026-09-28monthly0.5 https://app.readthrough.bio/stories/imperial-college-london-completes-action-hypertension-study-in-nigeria-4198492026-09-28monthly0.5 https://app.readthrough.bio/stories/astrazeneca-starts-phase-3-elecoglipron-trial-registers-two-more-studies-51104c2026-09-25monthly0.5 https://app.readthrough.bio/stories/nuvectis-pharma-registers-phase-1b-trial-of-nxp900-plus-lorlatinib-in-5c42e32026-09-28monthly0.5 https://app.readthrough.bio/stories/gsk-posts-propellant-trial-results-recruits-for-three-phase-3-6432fa2026-09-27monthly0.5 https://app.readthrough.bio/stories/axsome-registers-phase-3-long-term-safety-study-of-sunosi-in-pediatric-7186be2026-09-28monthly0.5 https://app.readthrough.bio/stories/sun-pharm-gets-manufacturing-supplement-approval-for-tadalafil-anda-828bed2026-09-28monthly0.5 https://app.readthrough.bio/stories/bms-updates-baraclude-labels-readies-navlimetostat-pk-study-and-liso-838aa12026-09-25monthly0.5 https://app.readthrough.bio/stories/lilly-registers-phase-3-depression-trial-posts-results-for-two-8668e72026-09-25monthly0.5 https://app.readthrough.bio/stories/zydus-pharms-gets-two-anda-actions-isotretinoin-label-supplement-8c19492026-09-28monthly0.5 https://app.readthrough.bio/stories/ionis-registers-phase-3-trial-of-obudanersen-for-angelman-syndrome-due-99c4ed2026-09-25monthly0.5 https://app.readthrough.bio/stories/amneal-s-generic-isotretinoin-gets-labeling-supplement-approved-by-fda-9ba4d92026-09-27monthly0.5 https://app.readthrough.bio/stories/johns-hopkins-registers-epidiolex-pilot-trial-for-presymptomatic-sturge-9e09d82026-09-28monthly0.5 https://app.readthrough.bio/stories/ptc-therapeutics-registers-phase-2a-trial-of-ptc844-in-rheumatoid-a1bbc82026-09-28monthly0.5 https://app.readthrough.bio/stories/merck-registers-phase-3-trial-testing-r-dxd-maintenance-in-advanced-a2dff02026-09-27monthly0.5 https://app.readthrough.bio/stories/teva-gets-fda-approval-for-generic-tofacitinib-citrate-er-two-claravis-a3d61f2026-09-28monthly0.5 https://app.readthrough.bio/stories/pfizer-posts-flu-covid-vaccine-trial-results-plans-phase-3-tilrekimig-ae241d2026-09-27monthly0.5 https://app.readthrough.bio/stories/exelixis-registers-phase-1-pediatric-trial-of-zanzalintinib-in-solid-c329ca2026-09-27monthly0.5 https://app.readthrough.bio/stories/sanofi-advances-belumosudil-phase-3-in-cgvhd-h5n8-flu-vaccine-study-c403a42026-09-27monthly0.5 https://app.readthrough.bio/stories/oruka-therapeutics-registers-phase-2-study-of-orka-002-in-hidradenitis-c7b7702026-09-28monthly0.5 https://app.readthrough.bio/stories/roche-registers-two-phase-ii-trials-of-ro7568282-in-parkinson-s-and-cac9952026-09-27monthly0.5 https://app.readthrough.bio/stories/larimar-registers-phase-3-forward-fa-trial-of-nomlabofusp-for-d965dd2026-09-28monthly0.5 https://app.readthrough.bio/stories/abbvie-posts-results-from-terminated-emraclidine-trial-opens-two-e8fb4f2026-09-27monthly0.5 https://app.readthrough.bio/stories/argenx-opens-phase-1-bioequivalence-trial-comparing-efgartigimod-f3d2292026-09-28monthly0.5 https://app.readthrough.bio/stories/regeneron-lists-vonsetamig-as-available-under-compassionate-use-program-f4d94f2026-09-27monthly0.5 https://app.readthrough.bio/stories/completed-trial-compares-iheezo-to-standard-anesthesia-for-intravitreal-fa50262026-09-28monthly0.5 https://app.readthrough.bio/stories/novo-nordisk-posts-results-for-two-semaglutide-trials-opens-new-nnc0487-12de6c2026-09-25monthly0.5 https://app.readthrough.bio/stories/korro-bio-registers-phase-1-2-trial-of-krro-121-for-urea-cycle-disorders-152c632026-09-28monthly0.5 https://app.readthrough.bio/stories/lilly-posts-orforglipron-phase-3-results-registers-new-obesity-copd-1688b72026-09-25monthly0.5 https://app.readthrough.bio/stories/amneal-wins-fda-labeling-approval-for-generic-doxycycline-hyclate-43e8d52026-09-27monthly0.5 https://app.readthrough.bio/stories/glenmark-wins-fda-approvals-for-fluticasone-nasal-spray-rosuvastatin-4ad3162026-09-28monthly0.5 https://app.readthrough.bio/stories/chong-kun-dang-collaborator-on-new-korean-registry-study-of-sglt2-glp-1-4d360a2026-09-28monthly0.5 https://app.readthrough.bio/stories/incyte-posts-results-for-phase-1-2-anti-pd-1-lag-3-tim-3-combo-trial-in-6fc0db2026-09-27monthly0.5 https://app.readthrough.bio/stories/astellas-registers-phase-1-2-gene-therapy-trial-for-asp2767-in-glaucoma-709c422026-09-28monthly0.5 https://app.readthrough.bio/stories/fda-clears-five-anda-supplements-for-teva-and-actavis-labs-generics-a407532026-09-28monthly0.5 https://app.readthrough.bio/stories/ocugen-registers-phase-3-trial-of-ocu410-gene-therapy-for-geographic-a66e2d2026-09-28monthly0.5 https://app.readthrough.bio/stories/roche-s-glofitamab-phase-2-trial-in-untreated-dlbcl-posts-results-after-bf01d32026-09-25monthly0.5 https://app.readthrough.bio/stories/incyte-linked-filings-this-week-fight-302-results-posted-new-academic-c7622b2026-09-27monthly0.5 https://app.readthrough.bio/stories/kardigan-registers-phase-3-open-label-extension-for-danicamtiv-in-cc5c4c2026-09-27monthly0.5 https://app.readthrough.bio/stories/cocrystal-pharma-posts-phase-1-results-for-cdi-988-an-oral-sars-cov-2-d0c1382026-09-28monthly0.5 https://app.readthrough.bio/stories/ocuphire-s-phase-3-vega-3-presbyopia-trial-posts-results-on-dbff052026-09-28monthly0.5 https://app.readthrough.bio/stories/insmed-registers-phase-1-trial-testing-ins1033-in-healthy-volunteers-dd870d2026-09-25monthly0.5 https://app.readthrough.bio/stories/argenx-registers-phase-2-trial-of-argx-121-in-iga-nephropathy-dec2902026-09-28monthly0.5 https://app.readthrough.bio/stories/pfizer-posts-hemophilia-results-opens-eczema-phase-3-ends-two-skin-ee53e02026-09-25monthly0.5 https://app.readthrough.bio/stories/kite-s-zuma-2-cohort-3-trial-in-btki-naive-mantle-cell-lymphoma-f1dee02026-09-27monthly0.5 https://app.readthrough.bio/stories/cellectar-registers-phase-3-trial-comparing-iopofosine-i-131-to-r-cd-in-03a82f2026-09-28monthly0.5 https://app.readthrough.bio/stories/voyager-therapeutics-registers-phase-1-dose-escalation-trial-of-vy1706-09c6082026-09-28monthly0.5 https://app.readthrough.bio/stories/madrigal-registers-pediatric-phase-2a-trial-of-resmetirom-for-mash-49769b2026-09-25monthly0.5 https://app.readthrough.bio/stories/xbiotech-posts-phase-1-results-for-natrunix-dose-escalation-study-in-6b3be92026-09-28monthly0.5 https://app.readthrough.bio/stories/abbvie-posts-crohn-s-ole-results-registers-phase-3-lung-cancer-and-7205882026-09-25monthly0.5 https://app.readthrough.bio/stories/eyecbetter-registers-trial-testing-non-contact-eye-pressure-device-7424762026-09-28monthly0.5 https://app.readthrough.bio/stories/bms-posts-jakarta-phase-3-results-updates-opdivo-label-registers-806ebe2026-09-25monthly0.5 https://app.readthrough.bio/stories/axsome-posts-advance-2-agitation-results-smoking-cessation-trial-a213cc2026-09-28monthly0.5 https://app.readthrough.bio/stories/siriraj-glaucoma-survey-completes-in-bangkok-basic-s-vascular-pilot-not-b0389f2026-09-28monthly0.5 https://app.readthrough.bio/stories/sun-pharma-logs-eleven-fda-labeling-supplements-and-two-rems-updates-in-be6b3f2026-09-28monthly0.5 https://app.readthrough.bio/stories/new-observational-study-registered-on-nt-probnp-monitoring-in-acute-c55ea52026-09-28monthly0.5 https://app.readthrough.bio/stories/assembly-biosciences-registers-phase-2-trial-of-abi-6250-for-chronic-c590f32026-09-28monthly0.5 https://app.readthrough.bio/stories/nextcure-s-nc410-pembrolizumab-trial-ends-after-phase-1b-part-2-never-d9abd42026-09-27monthly0.5 https://app.readthrough.bio/stories/humacyte-registers-two-symvess-trials-adolescent-phase-3-study-and-f5e8b42026-09-25monthly0.5 https://app.readthrough.bio/stories/spyre-therapeutics-registers-phase-2-skylight-trial-of-spy072-in-fb8f582026-09-28monthly0.5 https://app.readthrough.bio/stories/olaparib-results-posted-azd0120-car-t-trial-launches-three-fda-label-fe1fc22026-09-27monthly0.5 https://app.readthrough.bio/stories/vanderbilt-registers-phase-2-lazarus-trial-testing-it-therapy-to-fe36a92026-09-27monthly0.5 https://app.readthrough.bio/stories/crispr-therapeutics-registers-phase-1-2-trial-of-ctx340-for-treatment-0d372b2026-09-25monthly0.5 https://app.readthrough.bio/stories/agenus-posts-results-for-zalifrelimab-plus-balstilimab-trial-in-2618952026-09-28monthly0.5 https://app.readthrough.bio/stories/fda-clears-four-zydus-labeling-supplements-for-generic-diabetes-and-3670d02026-09-28monthly0.5 https://app.readthrough.bio/stories/vogenx-registers-phase-2b-trial-of-mizagliflozin-for-post-bariatric-4a79e72026-09-28monthly0.5 https://app.readthrough.bio/stories/genmab-terminates-phase-1-2-gen1055-trial-for-strategic-reasons-results-50a64e2026-09-27monthly0.5 https://app.readthrough.bio/stories/chung-shan-medical-university-registers-trial-on-slow-paced-breathing-813c172026-09-28monthly0.5 https://app.readthrough.bio/stories/terns-posts-phase-2a-falcon-results-for-oral-glp-1-candidate-tern-601-9910492026-09-27monthly0.5 https://app.readthrough.bio/stories/mylan-wins-fda-approval-for-labeling-supplement-on-metformin-er-tablets-9bad0a2026-09-28monthly0.5 https://app.readthrough.bio/stories/regeneron-registers-phase-1b-trial-of-factor-xi-xii-antibodies-in-a52ff42026-09-25monthly0.5 https://app.readthrough.bio/stories/roche-posts-results-for-satralizumab-ted-trial-completes-ocrelizumab-sc-a73b6c2026-09-25monthly0.5 https://app.readthrough.bio/stories/glenmark-posts-two-anda-labeling-supplement-approvals-for-metformin-ad1fe42026-09-28monthly0.5 https://app.readthrough.bio/stories/apnimed-posts-phase-2-mariposa-results-showing-ad109-cut-ahi4-versus-be9ff62026-09-28monthly0.5 https://app.readthrough.bio/stories/novartis-tour006-phase-2-results-posted-in-ckd-eltrombopag-pediatric-pk-c26dec2026-09-25monthly0.5 https://app.readthrough.bio/stories/denali-therapeutics-registers-phase-1-1b-trial-of-dnl921-in-alzheimer-s-d125c92026-09-28monthly0.5 https://app.readthrough.bio/stories/annovis-bio-registers-long-term-safety-study-of-buntanetap-in-alzheimer-d383ca2026-09-28monthly0.5 https://app.readthrough.bio/stories/argenx-posts-adapt-seron-phase-3-results-registers-new-phase-2-in-sj-dccb3a2026-09-28monthly0.5 https://app.readthrough.bio/stories/university-medical-center-mainz-registers-achilles-hf-trial-with-abbott-01d8232026-09-27monthly0.5 https://app.readthrough.bio/stories/md-anderson-registers-phase-ii-trial-of-summit-s-ivonescimab-in-rare-0b67502026-09-28monthly0.5 https://app.readthrough.bio/stories/shattuck-labs-registers-phase-2-trial-of-sl-325-in-crohn-s-disease-3eae442026-09-28monthly0.5 https://app.readthrough.bio/stories/yale-registers-gaucher-natural-history-study-with-sanofi-collaboration-3efe7c2026-09-25monthly0.5 https://app.readthrough.bio/stories/arrivent-registers-phase-1-trial-of-arr-002-in-ovarian-and-endometrial-85910b2026-09-28monthly0.5 https://app.readthrough.bio/stories/braveheart-bio-registers-phase-3-trial-of-bhb-1893-for-obstructive-hcm-8692452026-09-27monthly0.5 https://app.readthrough.bio/stories/synnovation-registers-phase-1-trial-of-snv1521-with-revolution-88c44c2026-09-27monthly0.5 https://app.readthrough.bio/stories/cspc-ouyi-gets-fda-labeling-approvals-for-metformin-hydrochloride-941a3c2026-09-28monthly0.5 https://app.readthrough.bio/stories/j-j-s-tecnis-den00v-iol-trial-terminated-for-business-reasons-results-9fc5102026-09-27monthly0.5 https://app.readthrough.bio/stories/washington-university-registers-phase-ib-trial-pairing-sip-t-with-n-803-bceed62026-09-27monthly0.5 https://app.readthrough.bio/stories/alkermes-registers-phase-2-trial-of-alks-7290-for-adult-adhd-cb2e322026-09-28monthly0.5 https://app.readthrough.bio/stories/scynexis-posts-results-for-terminated-phase-3-mario-trial-in-invasive-fab7812026-09-28monthly0.5 https://app.readthrough.bio/stories/takeda-gets-fda-labeling-approvals-for-actoplus-met-and-kazano-fb932b2026-09-27monthly0.5 https://app.readthrough.bio/stories/regeneron-registers-phase-1-regn17235-trial-and-joins-maryland-led-lung-0392182026-09-25monthly0.5 https://app.readthrough.bio/stories/novartis-registers-phase-2-vexas-trial-for-arumakimig-posts-ms-2192d52026-09-25monthly0.5 https://app.readthrough.bio/stories/arcus-casdatifan-two-new-trials-recruiting-hepatic-pk-study-and-rcc-37bb1e2026-09-27monthly0.5 https://app.readthrough.bio/stories/amgen-posts-rocket-shuttle-phase-3-rocatinlimab-results-neulasta-label-6783142026-09-25monthly0.5 https://app.readthrough.bio/stories/astrazeneca-saphnelo-label-update-baxdrostat-phase-3-results-posted-two-6b05c62026-09-25monthly0.5 https://app.readthrough.bio/stories/phathom-registers-phase-3-trial-testing-vonoprazan-for-episodic-78d5612026-09-28monthly0.5 https://app.readthrough.bio/stories/boehringer-registers-phase-iii-survodutide-trial-in-type-2-diabetes-a425f52026-10-01monthly0.5 https://app.readthrough.bio/stories/roche-results-post-for-two-terminated-morpheus-umbrella-trials-new-a6f6642026-09-27monthly0.5 https://app.readthrough.bio/stories/exelixis-registers-phase-3-stellar-316-trial-of-zanzalintinib-in-b870312026-09-27monthly0.5 https://app.readthrough.bio/stories/tuebingen-study-on-cardiac-amyloidosis-in-aortic-stenosis-lists-bayer-ca58092026-09-27monthly0.5 https://app.readthrough.bio/stories/actuate-linked-trial-of-9-ing-41-plus-carboplatin-in-salivary-gland-cecf102026-09-28monthly0.5 https://app.readthrough.bio/stories/abbvie-registers-three-new-trials-spanning-obesity-head-and-neck-cancer-d9ee502026-09-25monthly0.5 https://app.readthrough.bio/stories/sanofi-posts-results-across-four-trials-rsv-toddler-study-opal-ended-dcb7c02026-09-27monthly0.5 https://app.readthrough.bio/stories/arcutis-posts-pediatric-pk-results-for-topical-roflumilast-in-plaque-e08b612026-09-28monthly0.5 https://app.readthrough.bio/stories/bristol-myers-squibb-registers-observational-study-of-first-line-e21a482026-09-25monthly0.5 https://app.readthrough.bio/stories/actavis-labs-ut-s-clindamycin-benzoyl-peroxide-gel-anda-shows-fda-f6709b2026-09-28monthly0.5 https://app.readthrough.bio/stories/njcri-registers-transgender-liver-health-study-with-gilead-as-1913bc2026-09-27monthly0.5 https://app.readthrough.bio/stories/fda-approves-labeling-supplement-for-lexicon-s-inpefa-sotagliflozin-20e0192026-09-27monthly0.5 https://app.readthrough.bio/stories/gsk-linked-trials-six-new-registrations-this-week-all-not-yet-recruiting-230c992026-09-27monthly0.5 https://app.readthrough.bio/stories/cardurion-registers-phase-2-calibrate-hf-trial-of-camkii-inhibitor-crd-60ceae2026-09-28monthly0.5 https://app.readthrough.bio/stories/two-new-trials-registered-tavi-closure-device-study-and-aldosterone-a819e42026-09-28monthly0.5 https://app.readthrough.bio/stories/arvinas-registers-first-in-human-phase-1-2-trial-of-arv-6723-in-d5085b2026-09-28monthly0.5 https://app.readthrough.bio/stories/arrowhead-posts-phase-1-2a-results-for-inhaled-aro-mmp7-in-ipf-trial-e776c52026-09-25monthly0.5 https://app.readthrough.bio/stories/janssen-registers-new-phase-1-klk2-adc-trial-in-prostate-cancer-and-014ae12026-09-28monthly0.5 https://app.readthrough.bio/stories/amneal-wins-two-labeling-supplement-approvals-for-extended-release-1ee3ee2026-09-27monthly0.5 https://app.readthrough.bio/stories/argenx-registers-phase-3-trial-of-adimanebart-in-rare-congenital-2cfc1d2026-09-28monthly0.5 https://app.readthrough.bio/stories/alkermes-registers-expanded-access-program-for-pediatric-lybalvi-2db79a2026-09-28monthly0.5 https://app.readthrough.bio/stories/mylan-gets-anda-labeling-supplement-approved-for-fenofibrate-tablets-3c86862026-09-28monthly0.5 https://app.readthrough.bio/stories/pliant-s-beacon-ipf-trial-terminated-after-dsmb-recommendation-results-44d7e02026-09-28monthly0.5 https://app.readthrough.bio/stories/monte-rosa-registers-phase-2-trial-pairing-mrt-2359-with-apalutamide-in-4e818a2026-09-28monthly0.5 https://app.readthrough.bio/stories/novo-nordisk-registers-phase-3-cagrilintide-trial-penn-semaglutide-575aa42026-09-25monthly0.5 https://app.readthrough.bio/stories/deciphera-registers-phase-1-drug-interaction-study-of-vimseltinib-with-61f6fc2026-09-28monthly0.5 https://app.readthrough.bio/stories/iovance-registers-two-new-trials-iov-5001-solid-tumor-study-and-73f2452026-09-27monthly0.5 https://app.readthrough.bio/stories/lilly-wins-two-label-supplements-orforglipron-oral-tablet-and-9bed3d2026-09-25monthly0.5 https://app.readthrough.bio/stories/glenmark-recalls-azelaic-acid-gel-15-over-grainy-texture-complaints-9d17042026-09-28monthly0.5 https://app.readthrough.bio/stories/prime-medicine-registers-phase-1-2-trial-of-pm577a-prime-editing-9d40912026-09-28monthly0.5 https://app.readthrough.bio/stories/aligos-posts-phase-1-results-for-alg-097558-in-hepatic-impairment-study-c868252026-09-28monthly0.5 https://app.readthrough.bio/stories/xbiotech-posts-results-for-xb2001-pancreatic-cancer-trial-over-five-f230782026-09-28monthly0.5 https://app.readthrough.bio/stories/fda-approves-manufacturing-supplement-for-orenitram-tablets-from-united-f2a7352026-09-27monthly0.5 https://app.readthrough.bio/stories/verastem-registers-open-label-extension-study-for-avutometinib-f595602026-09-27monthly0.5 https://app.readthrough.bio/stories/roche-posts-satrago-1-phase-iii-results-cellcept-gets-seven-part-label-00b5192026-09-25monthly0.5 https://app.readthrough.bio/stories/rockif-trial-of-defactinib-in-ovarian-cancer-terminated-for-lost-07ef7c2026-09-27monthly0.5 https://app.readthrough.bio/stories/universiti-sains-malaysia-updates-registry-record-nct07741812-not-yet-1f8e1a2026-09-28monthly0.5 https://app.readthrough.bio/stories/polaryx-registers-phase-2-basket-trial-of-plx-200-across-four-pediatric-2d69632026-09-28monthly0.5 https://app.readthrough.bio/stories/iovance-s-cervical-cancer-til-trial-c-145-04-terminated-after-meeting-3217182026-09-27monthly0.5 https://app.readthrough.bio/stories/results-post-for-old-usc-gastric-cancer-trial-bristol-myers-squibb-3623392026-09-27monthly0.5 https://app.readthrough.bio/stories/outlook-therapeutics-posts-phase-3-results-for-ons-5010-in-wet-amd-trial-3f26dd2026-09-28monthly0.5 https://app.readthrough.bio/stories/new-phase-2a-trial-registered-for-amgen-s-xaluritamig-after-lutetium-435b852026-09-25monthly0.5 https://app.readthrough.bio/stories/mcgill-university-health-centre-research-institute-of-the-mcgill-5bc3972026-09-28monthly0.5 https://app.readthrough.bio/stories/ascendis-pharma-bone-s-yorvipath-gets-labeling-supplement-approved-by-5dcaa92026-09-28monthly0.5 https://app.readthrough.bio/stories/boehringer-ingelheim-registers-phase-i-trial-of-immunotherapy-bi-6b111f2026-10-01monthly0.5 https://app.readthrough.bio/stories/polish-myeloma-consortium-registers-phase-3-titan-trial-with-j-j-drugs-6cd0e52026-09-27monthly0.5 https://app.readthrough.bio/stories/lilly-posts-phase-2-mazisotine-results-for-diabetic-nerve-pain-72213a2026-09-27monthly0.5 https://app.readthrough.bio/stories/fda-approves-rems-related-supplement-for-lynozyfic-linvoseltamab-gcpt-77e30c2026-09-27monthly0.5 https://app.readthrough.bio/stories/md-anderson-registers-phase-2-trial-of-summit-s-ivonescimab-in-rare-a559f92026-09-28monthly0.5 https://app.readthrough.bio/stories/cullinan-therapeutics-registers-phase-1b-2a-trial-of-velinotamig-in-itp-a8cc692026-09-28monthly0.5 https://app.readthrough.bio/stories/astrazeneca-posts-phase-iii-baxdrostat-hypertension-results-registers-c8d87d2026-09-25monthly0.5 https://app.readthrough.bio/stories/novo-nordisk-registers-korean-masld-mash-real-world-study-and-ceec052026-09-25monthly0.5 https://app.readthrough.bio/stories/novartis-myfortic-label-update-approved-m-d-anderson-posts-endometrial-d455d02026-09-25monthly0.5 https://app.readthrough.bio/stories/atrium-therapeutics-recruiting-for-phase-1-2-atr-1072-trial-in-prkag2-d801b92026-09-25monthly0.5 https://app.readthrough.bio/stories/nuvation-bio-registers-phase-1-famotidine-interaction-study-for-dfd7ef2026-09-27monthly0.5 https://app.readthrough.bio/stories/abbvie-week-botox-oral-pain-results-post-new-cll-myeloma-abbv-859-e194362026-09-27monthly0.5 https://app.readthrough.bio/stories/vanda-s-hetlioz-gets-manufacturing-supplement-approval-from-fda-005cfd2026-09-28monthly0.5 https://app.readthrough.bio/stories/zydus-pharms-gets-three-fda-supplement-approvals-in-one-week-for-0a5db92026-09-28monthly0.5 https://app.readthrough.bio/stories/alterity-registers-open-label-extension-for-ath434-in-french-msa-3169702026-09-28monthly0.5 https://app.readthrough.bio/stories/compass-therapeutics-posts-phase-2-results-for-ctx-009-in-metastatic-3457aa2026-09-28monthly0.5 https://app.readthrough.bio/stories/healthpartners-tdap-lactation-study-completed-sanofi-listed-as-364e0c2026-09-25monthly0.5 https://app.readthrough.bio/stories/gland-pharma-wins-anda-approval-for-generic-sugammadex-sodium-injection-366bcb2026-09-28monthly0.5 https://app.readthrough.bio/stories/spruce-biosciences-expanded-access-program-for-tralesinidase-alfa-in-3d17f82026-09-28monthly0.5 https://app.readthrough.bio/stories/oculis-posts-terminated-phase-3-ocs-01-cataract-trial-results-after-483e6e2026-09-28monthly0.5 https://app.readthrough.bio/stories/sinovac-completes-phase-i-trial-of-high-dose-flu-vaccine-in-adults-60-5adda02026-09-28monthly0.5 https://app.readthrough.bio/stories/kodiak-sciences-recruiting-phase-3-alto-trial-testing-tabirafusp-5e8e162026-09-28monthly0.5 https://app.readthrough.bio/stories/jazz-registers-phase-3b-4-trial-testing-gradual-cbd-os-titration-in-6a2fb22026-09-27monthly0.5 https://app.readthrough.bio/stories/ionis-registers-phase-3-pediatric-study-of-olezarsen-for-fcs-6ad3e52026-09-25monthly0.5 https://app.readthrough.bio/stories/sun-pharma-gets-anda-nod-for-sugammadex-two-metformin-labeling-70c9ac2026-09-28monthly0.5 https://app.readthrough.bio/stories/yale-registers-phase-2-trial-of-tonix-s-tnx-1900-for-pituitary-surgery-75f1382026-09-28monthly0.5 https://app.readthrough.bio/stories/teva-gets-anda-approval-for-sugammadex-sodium-injection-four-87a60b2026-09-28monthly0.5 https://app.readthrough.bio/stories/trial-registered-for-tafasitamab-plus-rituximab-in-newly-diagnosed-be66322026-09-27monthly0.5 https://app.readthrough.bio/stories/pfizer-registers-phase-3-trials-in-alopecia-areata-and-chronic-migraine-bf6f452026-09-25monthly0.5 https://app.readthrough.bio/stories/dana-farber-registers-phase-2-trial-of-agenus-drugs-in-early-rectal-daaeb62026-09-28monthly0.5 https://app.readthrough.bio/stories/amneal-wins-fda-supplement-approval-for-mycophenolate-mofetil-oral-db99ce2026-09-27monthly0.5 https://app.readthrough.bio/stories/humacyte-posts-trauma-trial-results-registers-new-phase-2a-coronary-eb3ff92026-09-25monthly0.5 https://app.readthrough.bio/stories/beone-medicines-registers-phase-2-tislelizumab-dosing-study-in-japanese-f6e1252026-09-29monthly0.5 https://app.readthrough.bio/stories/cullinan-therapeutics-registers-phase-1b-trial-of-cln-049-with-05e3e72026-09-28monthly0.5 https://app.readthrough.bio/stories/gemelli-registers-interventional-ev-trial-mapping-vascular-1022612026-09-28monthly0.5 https://app.readthrough.bio/stories/krystal-biotech-registers-early-phase-trial-of-kb111-gene-therapy-for-11149f2026-09-28monthly0.5 https://app.readthrough.bio/stories/jazz-pharmaceuticals-registers-two-phase-2-3-and-phase-3-trials-for-cbd-1337a02026-09-27monthly0.5 https://app.readthrough.bio/stories/montefiore-registers-phase-1-trial-pairing-talquetamab-with-belantamab-1e6f9d2026-09-27monthly0.5 https://app.readthrough.bio/stories/sanofi-s-week-avapro-label-update-new-belumosudil-be-study-two-tb-trial-2295c72026-09-25monthly0.5 https://app.readthrough.bio/stories/amneal-s-generic-bosentan-gets-two-labeling-supplements-approved-by-fda-2528522026-09-27monthly0.5 https://app.readthrough.bio/stories/zydus-wins-two-new-generic-approvals-edaravone-and-fluvoxamine-er-plus-28b2ee2026-09-28monthly0.5 https://app.readthrough.bio/stories/novo-nordisk-registers-phase-3-obesity-trial-for-zenagamtide-mtc-safety-2b5c522026-09-25monthly0.5 https://app.readthrough.bio/stories/context-therapeutics-posts-results-for-terminated-elacestrant-2fd09e2026-09-28monthly0.5 https://app.readthrough.bio/stories/abeona-therapeutics-inc-updates-registry-record-nct07717736-not-yet-325b9f2026-09-28monthly0.5 https://app.readthrough.bio/stories/biogen-phase-2-felzartamab-trial-in-graves-disease-recruiting-since-3525022026-09-27monthly0.5 https://app.readthrough.bio/stories/brii-biosciences-posts-phase-2-results-for-brii-835-brii-179-hepatitis-46bb472026-09-28monthly0.5 https://app.readthrough.bio/stories/bms-week-two-label-updates-new-luspatercept-ckd-trial-pulmonary-4aae492026-09-27monthly0.5 https://app.readthrough.bio/stories/viatris-collaborated-trial-registered-comparing-yupelri-perforomist-4eee3e2026-09-28monthly0.5 https://app.readthrough.bio/stories/nucana-s-nutide-303-trial-for-nuc-3373-combos-terminated-results-posted-565fd82026-09-28monthly0.5 https://app.readthrough.bio/stories/urogen-registers-phase-1-dose-escalation-trial-of-ugn-501-in-recurrent-76353d2026-09-28monthly0.5 https://app.readthrough.bio/stories/novartis-posts-assist-phase-2-results-two-pediatric-studies-listed-780cb12026-09-28monthly0.5 https://app.readthrough.bio/stories/lexeo-registers-phase-2-crossover-trial-of-lx2006-gene-therapy-for-7a020d2026-09-27monthly0.5 https://app.readthrough.bio/stories/barda-sponsored-phase-2-h5-flu-vaccine-trial-posts-results-comparing-7b812e2026-09-28monthly0.5 https://app.readthrough.bio/stories/atea-registers-phase-1-first-in-human-trial-of-at-587-for-hepatitis-e-7bee522026-09-28monthly0.5 https://app.readthrough.bio/stories/merck-registers-phase-2-3-trial-of-bomedemstat-versus-standard-810fac2026-09-29monthly0.5 https://app.readthrough.bio/stories/boehringer-ingelheim-posts-completed-bioequivalence-trial-of-two-8abbed2026-09-30monthly0.5 https://app.readthrough.bio/stories/gilead-s-gs-0415-recruiting-in-phase-1-hiv-trial-testing-sc-iv-dosing-8c6e9d2026-09-27monthly0.5 https://app.readthrough.bio/stories/ucb-registers-phase-2-scala-trial-of-galvokimig-in-copd-with-chronic-97ae212026-09-28monthly0.5 https://app.readthrough.bio/stories/sol-gel-posts-terminated-phase-2-patidegib-gel-trial-results-2-of-47-9c414f2026-09-28monthly0.5 https://app.readthrough.bio/stories/immunomic-therapeutics-opens-phase-1-trial-of-iti-9001-for-japanese-red-a11f442026-09-28monthly0.5 https://app.readthrough.bio/stories/astrazeneca-registers-phase-iii-bladder-cancer-trial-joins-natera-led-a24c2e2026-09-25monthly0.5 https://app.readthrough.bio/stories/india-registers-ckms-observational-registry-backed-by-sun-pharmaceutical-aa1a032026-09-28monthly0.5 https://app.readthrough.bio/stories/amgen-posts-results-for-three-rocatinlimab-phase-3-trials-plus-ac5a022026-09-25monthly0.5 https://app.readthrough.bio/stories/oric-pharmaceuticals-registers-phase-3-himalayas-1-trial-for-acf3982026-09-27monthly0.5 https://app.readthrough.bio/stories/ocrevus-higher-dose-phase-3-gavotte-posts-results-roche-also-tied-to-adf25a2026-09-25monthly0.5 https://app.readthrough.bio/stories/hutchmed-registers-first-in-human-phase-i-iia-trial-of-hmpl-a830-in-b341482026-09-27monthly0.5 https://app.readthrough.bio/stories/axsome-registers-two-phase-3-solriamfetol-trials-in-pediatric-and-b59d1b2026-09-28monthly0.5 https://app.readthrough.bio/stories/kyntra-bio-registers-phase-3-roxadustat-trial-for-anemia-in-lower-risk-c8b59b2026-09-28monthly0.5 https://app.readthrough.bio/stories/pfizer-week-aml-donor-leukocyte-trial-posts-results-three-early-trials-d6d7d52026-09-25monthly0.5 https://app.readthrough.bio/stories/new-rct-registered-comparing-robotic-assisted-vs-conventional-total-d9c2a02026-09-27monthly0.5 https://app.readthrough.bio/stories/finch-4-filgotinib-ra-extension-study-completes-results-posted-after-dd0d8f2026-09-28monthly0.5 https://app.readthrough.bio/stories/teva-gets-anda-approval-for-tolvaptan-generic-ziac-label-updated-de557e2026-09-28monthly0.5 https://app.readthrough.bio/stories/outlook-therapeutics-posts-norse-three-results-for-ons-5010-in-retinal-0878e52026-09-28monthly0.5 https://app.readthrough.bio/stories/gsk-registers-six-new-studies-spanning-cardiovascular-vaccines-mash-cmv-0c4d202026-09-27monthly0.5 https://app.readthrough.bio/stories/ascendis-pharma-registers-phase-3-trial-of-yorvipath-in-adolescent-12af0c2026-09-28monthly0.5 https://app.readthrough.bio/stories/merck-registers-phase-2-mk-1045-trial-in-b-cell-cancers-letermovir-cmv-1b99c12026-09-28monthly0.5 https://app.readthrough.bio/stories/fda-approves-labeling-supplement-for-zydus-gabapentin-anda-21c9562026-09-28monthly0.5 https://app.readthrough.bio/stories/west-china-hospital-starts-phase-2-vericiguat-trial-for-calcific-aortic-23e6b52026-09-27monthly0.5 https://app.readthrough.bio/stories/nuvation-bio-registers-two-new-trials-for-idh1-mutant-glioma-drug-28da872026-09-27monthly0.5 https://app.readthrough.bio/stories/sanofi-posts-rilzabrutinib-atopic-dermatitis-results-opens-phase-3-2c45f62026-09-28monthly0.5 https://app.readthrough.bio/stories/xencor-s-phase-1-trial-of-xmab412-in-healthy-volunteers-is-recruiting-2cc44c2026-09-28monthly0.5 https://app.readthrough.bio/stories/bms-trials-post-results-across-lung-cancer-sarcoma-myelofibrosis-new-6513982026-09-28monthly0.5 https://app.readthrough.bio/stories/actuate-registers-phase-1-2-trial-of-oral-elraglusib-in-advanced-solid-67e28b2026-09-28monthly0.5 https://app.readthrough.bio/stories/mirum-registers-phase-1-adme-trial-for-mrm-3379-in-healthy-male-6985aa2026-09-28monthly0.5 https://app.readthrough.bio/stories/roche-posts-results-for-two-phase-3-lebrikizumab-asthma-trials-operetta-6a235f2026-09-25monthly0.5 https://app.readthrough.bio/stories/nektar-registers-phase-3-zenith-ad-2-trial-of-rezpegaldesleukin-in-77afe22026-09-28monthly0.5 https://app.readthrough.bio/stories/novo-nordisk-recruiting-for-two-ubt251-phase-1-drug-interaction-studies-83bea02026-09-27monthly0.5 https://app.readthrough.bio/stories/boehringer-ingelheim-registers-phase-ib-ii-trial-pairing-obrixtamig-8634222026-09-30monthly0.5 https://app.readthrough.bio/stories/astrazeneca-posts-passage-phase-4-tezepelumab-results-registers-new-920f2e2026-09-27monthly0.5 https://app.readthrough.bio/stories/anixa-biosciences-linked-tnbc-vaccine-trial-posts-completed-results-98f5102026-09-28monthly0.5 https://app.readthrough.bio/stories/nexcella-registers-phase-3-nexicart-3-trial-of-car-t-nxc-201-in-al-9b84c02026-09-28monthly0.5 https://app.readthrough.bio/stories/boehringer-ingelheim-registers-phase-i-mass-balance-trial-for-bi-3034701-a93a4f2026-10-01monthly0.5 https://app.readthrough.bio/stories/lilly-completes-phase-3-attain-j-trial-of-oral-orforglipron-in-japanese-ad231d2026-09-25monthly0.5 https://app.readthrough.bio/stories/university-of-rijeka-completes-pilot-trial-on-mindfulness-forest-b301fe2026-09-28monthly0.5 https://app.readthrough.bio/stories/dana-farber-registers-phase-2-zanzalintinib-trial-for-rare-adrenal-c516d72026-09-27monthly0.5 https://app.readthrough.bio/stories/results-posted-for-onapristone-anastrozole-trial-in-refractory-cd0e402026-09-28monthly0.5 https://app.readthrough.bio/stories/mylan-doxepin-label-update-approved-viatris-linked-contact-lens-comfort-d429222026-09-28monthly0.5 https://app.readthrough.bio/stories/pfizer-posts-results-for-two-completed-phase-2-studies-breast-cancer-d5f2f82026-09-25monthly0.5 https://app.readthrough.bio/stories/gilead-registers-phase-2-3-hiv-combo-trial-and-phase-1-oncology-study-db79422026-09-27monthly0.5 https://app.readthrough.bio/stories/fda-approves-labeling-supplement-for-sun-pharma-s-generic-rosuvastatin-e6b5182026-09-28monthly0.5 https://app.readthrough.bio/stories/lilly-posts-results-for-five-completed-phase-1-studies-opens-three-new-f08c3d2026-09-25monthly0.5 https://app.readthrough.bio/stories/beigene-posts-phase-2-results-for-tislelizumab-combos-in-head-and-neck-f123dc2026-09-27monthly0.5 https://app.readthrough.bio/stories/regeneron-registers-phase-3-picc-clot-prevention-trial-sanofi-runs-f141f42026-09-25monthly0.5 https://app.readthrough.bio/stories/amgen-posts-terminated-sotorasib-nsclc-trial-results-approves-neupogen-f2eae12026-09-25monthly0.5 https://app.readthrough.bio/stories/j-j-s-tecnis-iol-trial-posts-results-ebola-vaccine-study-also-completed-f379b12026-09-27monthly0.5 https://app.readthrough.bio/stories/new-trial-registered-for-songling-xuemaikang-capsules-in-hypertension-f3b4a62026-09-28monthly0.5 https://app.readthrough.bio/stories/washington-university-registers-phase-2-trial-of-cemiplimab-in-kidney-f4c2c52026-09-27monthly0.5 https://app.readthrough.bio/stories/novartis-posts-pelacarsen-phase-3-apheresis-results-updates-three-drug-fc94a32026-09-28monthly0.5 https://app.readthrough.bio/stories/abbott-registers-voyager-ce-trial-for-encantor-tavi-system-in-aortic-07af912026-09-28monthly0.5 https://app.readthrough.bio/stories/biontech-recruiting-for-bnt168-hiv-vaccine-phase-i-ii-trial-0a7bb02026-09-27monthly0.5 https://app.readthrough.bio/stories/astrazeneca-posts-natron-phase-iii-benralizumab-results-registers-rosy-0f7afc2026-09-25monthly0.5 https://app.readthrough.bio/stories/lilly-posts-surpass-cvot-results-tirzepatide-compared-to-dulaglutide-on-212fd92026-09-27monthly0.5 https://app.readthrough.bio/stories/g-rond-if-opens-reference-ai-trial-testing-ai-echocardiography-in-55674f2026-09-28monthly0.5 https://app.readthrough.bio/stories/ars-pharmaceuticals-posts-phase-2-results-for-intranasal-epinephrine-5d52092026-09-28monthly0.5 https://app.readthrough.bio/stories/ferring-wins-fda-approval-for-label-update-to-stimate-nasal-spray-5f36182026-09-28monthly0.5 https://app.readthrough.bio/stories/keros-lists-phase-2-trial-of-ker-065-in-duchenne-muscular-dystrophy-on-70b7662026-09-28monthly0.5 https://app.readthrough.bio/stories/novo-nordisk-registers-phase-1-study-of-oral-obesity-candidate-nnc6022-7ba0d72026-09-25monthly0.5 https://app.readthrough.bio/stories/novartis-posts-bioitalee-results-registers-three-new-observational-and-9ada752026-09-25monthly0.5 https://app.readthrough.bio/stories/mbx-biosciences-registers-phase-3-trial-of-canvuparatide-for-9b30402026-09-28monthly0.5 https://app.readthrough.bio/stories/janssen-wins-fda-labeling-approvals-for-sporanox-capsule-and-oral-a366672026-09-27monthly0.5 https://app.readthrough.bio/stories/hutchmed-completes-phase-1-drug-interaction-study-for-hmpl-453-tartrate-a6fa4f2026-09-27monthly0.5 https://app.readthrough.bio/stories/fda-approves-teva-s-generic-eltrombopag-olamine-tablets-in-three-aa7e2a2026-09-28monthly0.5 https://app.readthrough.bio/stories/maze-therapeutics-recruiting-phase-2-trial-of-mze782-tablets-in-adult-baf2092026-09-27monthly0.5 https://app.readthrough.bio/stories/abbvie-updates-registry-record-nct07697456-recruiting-c2a28d2026-09-28monthly0.5 https://app.readthrough.bio/stories/gsk-posts-bepirovirsen-qt-results-registers-mo-rez-ovarian-endometrial-d3499f2026-09-27monthly0.5 https://app.readthrough.bio/stories/penn-medicine-registers-picstat-pilot-testing-cd8-pet-imaging-with-d8a2072026-09-27monthly0.5 https://app.readthrough.bio/stories/tscan-therapeutics-registers-phase-3-trial-of-tsc-101-for-aml-and-mds-d8de1a2026-09-28monthly0.5 https://app.readthrough.bio/stories/abeona-registers-long-term-safety-registry-for-zevaskyn-gene-therapy-in-d99de92026-09-28monthly0.5 https://app.readthrough.bio/stories/vcu-registers-end-ext-natural-history-study-for-myotonic-dystrophy-type-dfc96d2026-09-27monthly0.5 https://app.readthrough.bio/stories/sanofi-posts-sar443579-aml-trial-results-opens-new-sar445877-gastric-ed84fc2026-09-27monthly0.5 https://app.readthrough.bio/stories/galectin-therapeutics-posts-results-for-belapectin-hepatic-impairment-f477bb2026-09-28monthly0.5 https://app.readthrough.bio/stories/incyte-linked-ruxolitinib-trials-post-results-both-mgh-and-ut-f6f9682026-09-27monthly0.5 https://app.readthrough.bio/stories/tiziana-registers-phase-2a-banyan-trial-of-nasal-foralumab-in-als-0ca3f52026-09-28monthly0.5 https://app.readthrough.bio/stories/novo-nordisk-posts-phase-3-icodec-vs-glargine-results-registers-two-1184052026-09-25monthly0.5 https://app.readthrough.bio/stories/ptc-therapeutics-registers-phase-3-prove-fa-trial-for-vatiquinone-in-16b9a02026-09-28monthly0.5 https://app.readthrough.bio/stories/roche-s-lebrikizumab-asthma-trial-posts-results-new-faricimab-trial-3af0942026-09-25monthly0.5 https://app.readthrough.bio/stories/regeneron-s-phase-2-olatorepatide-obesity-trial-recruiting-across-five-4312132026-09-25monthly0.5 https://app.readthrough.bio/stories/zydus-pharms-gets-two-fda-label-supplement-approvals-for-4c333c2026-09-28monthly0.5 https://app.readthrough.bio/stories/agomab-registers-phase-2b-trial-of-ontunisertib-in-fibrostenosing-crohn-4cb9c42026-09-28monthly0.5 https://app.readthrough.bio/stories/glenmark-s-generic-nintedanib-esylate-capsules-anda212555-listed-as-4f40f02026-09-28monthly0.5 https://app.readthrough.bio/stories/nektar-registers-phase-3-atopic-dermatitis-trial-for-rezpegaldesleukin-51afae2026-09-28monthly0.5 https://app.readthrough.bio/stories/aligos-posts-results-for-alg-097558-renal-impairment-pk-study-trial-5fc04c2026-09-28monthly0.5 https://app.readthrough.bio/stories/astrazeneca-posts-phase-3-results-for-pt010-asthma-trials-logos-and-669f992026-09-25monthly0.5 https://app.readthrough.bio/stories/gilead-registers-two-phase-3-trials-of-lenacapavir-long-acting-regimen-675f182026-09-27monthly0.5 https://app.readthrough.bio/stories/amneal-wins-fda-approval-for-methylergonovine-maleate-labeling-702df52026-09-27monthly0.5 https://app.readthrough.bio/stories/genmab-biontech-trial-of-gen1042-combos-ends-early-after-phase-1-review-74fd422026-09-27monthly0.5 https://app.readthrough.bio/stories/abbvie-posts-temple-phase-3-results-for-atogepant-vs-topiramate-opens-77e4942026-09-27monthly0.5 https://app.readthrough.bio/stories/united-therapeutics-posts-results-for-terminated-phase-3-ralinepag-cpet-79cd242026-09-28monthly0.5 https://app.readthrough.bio/stories/abbvie-registers-two-real-world-studies-for-atogepant-and-mirvetuximab-79f3eb2026-09-25monthly0.5 https://app.readthrough.bio/stories/academisch-medisch-centrum-universiteit-van-amsterdam-amc-uva-updates-7a30932026-09-28monthly0.5 https://app.readthrough.bio/stories/amgen-registers-two-phase-3-extension-trials-for-obesity-drug-7df2b22026-09-27monthly0.5 https://app.readthrough.bio/stories/pfizer-recruiting-phase-4-rimegepant-safety-study-in-india-for-triptan-80c9d42026-09-27monthly0.5 https://app.readthrough.bio/stories/bursa-city-hospital-completes-retrospective-study-on-inflammatory-b131e02026-09-28monthly0.5 https://app.readthrough.bio/stories/compass-therapeutics-registers-phase-2-study-of-ctx-471-in-ncam-d310c32026-09-28monthly0.5 https://app.readthrough.bio/stories/yarrow-bioscience-registers-phase-2-trial-of-yb-101-in-graves-disease-dc1e1d2026-09-28monthly0.5 https://app.readthrough.bio/stories/entrada-registers-phase-2-long-term-extension-study-for-dmd-exon-e1e47d2026-09-28monthly0.5 https://app.readthrough.bio/stories/sanofi-posts-pediatric-hectorol-results-usc-germ-cell-trial-data-also-e1fec42026-09-28monthly0.5 https://app.readthrough.bio/stories/bms-completes-real-world-study-comparing-pomalidomide-and-non-f358df2026-09-25monthly0.5 https://app.readthrough.bio/stories/zhongmei-huadong-registers-phase-3-roflumilast-foam-trial-for-faa0812026-09-28monthly0.5 https://app.readthrough.bio/stories/beigene-posts-results-for-lbl-007-tislelizumab-combo-trial-in-03052d2026-09-27monthly0.5 https://app.readthrough.bio/stories/amckaus-registers-phase-2-trial-of-aom0304-for-hypertrophic-0964a22026-09-28monthly0.5 https://app.readthrough.bio/stories/kymera-registers-long-term-extension-study-for-kt-621-in-asthma-patients-0c12552026-09-28monthly0.5 https://app.readthrough.bio/stories/amgen-recalls-sensipar-and-corlanor-lots-bkemv-biosimilar-gets-label-13bf9a2026-09-25monthly0.5 https://app.readthrough.bio/stories/gsk-reports-dreamm-12-results-costar-lung-trial-nears-study-completion-15127e2026-09-27monthly0.5 https://app.readthrough.bio/stories/novartis-mayzent-label-update-approved-four-real-world-studies-2686352026-09-25monthly0.5 https://app.readthrough.bio/stories/bms-posts-prime-hcc-results-registers-phase-3-lung-trial-and-two-2811942026-09-25monthly0.5 https://app.readthrough.bio/stories/alkermes-inc-updates-registry-record-nct07680114-recruiting-2c75a42026-09-28monthly0.5 https://app.readthrough.bio/stories/fda-approves-labeling-supplement-for-sun-pharma-s-leqselvi-549f722026-09-28monthly0.5 https://app.readthrough.bio/stories/mannkind-registers-phase-2-trial-of-inhaled-nintedanib-for-pulmonary-574d652026-09-28monthly0.5 https://app.readthrough.bio/stories/cingulate-posts-phase-3-ctx-1301-classroom-results-in-adhd-more-than-6351452026-09-28monthly0.5 https://app.readthrough.bio/stories/zevra-therapeutics-posts-results-for-phase-2-sdx-trial-in-idiopathic-6591e82026-09-28monthly0.5 https://app.readthrough.bio/stories/regeneron-registers-phase-3-cat-allergy-trial-and-phase-1-2-glaucoma-7ea28f2026-09-25monthly0.5 https://app.readthrough.bio/stories/gilead-s-phase-2-obeldesivir-rsv-trial-terminated-by-sponsor-results-85d2952026-09-27monthly0.5 https://app.readthrough.bio/stories/fda-approves-labeling-supplement-for-actavis-s-orally-disintegrating-9d30312026-09-28monthly0.5 https://app.readthrough.bio/stories/ut-southwestern-registers-ripcord-trial-testing-psma-pet-guided-a261e12026-09-28monthly0.5 https://app.readthrough.bio/stories/tg-therapeutics-registers-two-phase-2-ublituximab-trials-in-afc3c62026-09-28monthly0.5 https://app.readthrough.bio/stories/lilly-reports-achieve-j-safety-results-label-updates-for-olumiant-afeb7a2026-09-25monthly0.5 https://app.readthrough.bio/stories/outlook-therapeutics-posts-norse-eight-phase-3-results-for-ons-5010-in-b07b212026-09-28monthly0.5 https://app.readthrough.bio/stories/getz-pharma-registers-community-ncd-screening-study-in-faisalabad-b0929f2026-09-28monthly0.5 https://app.readthrough.bio/stories/pfizer-s-crohn-s-trial-for-etrasimod-halted-rsv-pregnancy-study-reports-cdbd892026-09-25monthly0.5 https://app.readthrough.bio/stories/zydus-pharms-gets-fda-approvals-for-selenious-acid-anda-and-two-e5dff92026-09-28monthly0.5 https://app.readthrough.bio/stories/leo-pharma-s-anzupgo-cream-gets-labeling-supplement-approved-by-fda-ee9a362026-09-28monthly0.5 https://app.readthrough.bio/stories/annexon-posts-results-for-anx005-phase-2-waiha-study-completed-with-7-f4b5f62026-09-28monthly0.5 https://app.readthrough.bio/stories/agomab-spain-registers-phase-1-mass-balance-trial-of-ontunisertib-in-3ea1c82026-09-28monthly0.5 https://app.readthrough.bio/stories/argenx-registers-phase-2a-empasiprubart-trial-in-gmg-adimanebart-pk-826ee22026-09-28monthly0.5 https://app.readthrough.bio/stories/rhythm-pharmaceuticals-is-collaborator-on-new-german-real-world-82f7932026-09-28monthly0.5 https://app.readthrough.bio/stories/fda-approves-labeling-supplement-for-janssen-s-erleada-apalutamide-996f5c2026-09-27monthly0.5 https://app.readthrough.bio/stories/inmune-bio-posts-results-for-phase-2-xpro1595-trial-in-early-alzheimer-ea0be82026-09-28monthly0.5